Document is current
Any future updates will be listed below
-
Authors
Cukurova, Feyza
Gustavson, Britta P.
Griborio-Guzman, Andres G.
Levin, Leonard A.
-
Funding
Funding for this research was provided by:
Canada Research Chairs
Canadian Institutes of Health Research (PJT-162396)
National Eye Institute (R21EY025074)
- License Information
-
More Information
Article History
Received: 7 July 2021
Accepted: 21 March 2022
First Online: 15 April 2022
Competing interests
: LAL has served as a consultant or advisory board member on translational research and/or clinical trials to Aerie, Eyevensys, Galimedix, Genentech, Perfuse, Quark, Regenera, Roche, Santen, the Gilbert Family Foundation, and the National Eye Institute. FC, BG, and AGG do not have competing interests.
